CommercialCoverageMedium impact
Negative Pressure Wound Therapy (Vacuum-Assisted Closure) 1.01.38
Excellus BlueCross BlueShield·Wound Care, Dermatology, General Surgery +3 more·Skin (Dermatology)
Effective date
Sep 18, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield updated their Negative Pressure Wound Therapy (NPWT) policy effective September 18, 2025, establishing specific medical appropriateness criteria for powered NPWT devices while declaring non-powered and disposable systems investigational. The policy requires comprehensive documentation including weekly wound measurements and limits average treatment to 4-6 weeks.
Action Required
By September 18, 2025: Billing team must update prior authorization processes to ensure NPWT claims meet all new criteria including absence of contraindications (necrotic tissue, untreated osteomyelitis, malignancy in wound, exposed vasculature), appropriate indications (chronic stage III/IV pressure ulcers, neuropathic ulcers, surgical wound complications, or traumatic wounds), and comprehensive documentation requirements. Providers must document weekly wound measurements showing steady volume decrease and include detailed wound assessments. Claims for non-powered NPWT systems (SNaP, Prevena, PICO) will be denied as investigational.